Compare

IGF-1 DES vs Tirzepatide

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

Last reviewed . By the PeptIQ team.

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.

IGF-1 DES

2337 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 51% · Mixed 32% · Unfavorable overall 17%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Skin appearance
48
Appetite control
39
Energy
127
Mood
93
Focus
112

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Headache
144
GI discomfort
118
Dizziness
92
Fatigue
89
Nausea
111

Self-reported dose per injection

Median bucket: 0.4–0.6 mg · Most common: 0.2–0.4 mg

Reports span 0.05–2 mg

0.05–0.1 mg
7
0.1–0.2 mg
15
0.2–0.4 mg
18
0.4–0.6 mg
14
0.6–1 mg
8
1–2 mg
2

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing21stacking19side effects17igf-1 des20

How repeat users are trending

Among repeat reporters, 61% said they felt similar to their last entry, 43% more positive, and 21% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 23 days · Based on 514 repeat reporters

Tirzepatide

7 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 14% · Mixed 0% · Unfavorable overall 86%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Appetite
7
Sleep
1
Mood
1
Energy
1

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Nausea
3
Injection site irritation
3

Self-reported dose per injection

Median bucket: 5+ mg · Most common: 5+ mg

Reports span 0.4 to ≥ 5 mg (open-ended top bucket)

0.4–0.6 mg
1
5+ mg
6

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Sources (16)

Published sources linked on the IGF-1 DES and Tirzepatide wiki pages.

  1. PubMed

    Des(1-3)IGF-I: a truncated form of insulin-like growth factor-I

    Ballard FJ, Wallace JC, Francis GL, et al. Int J Biochem Cell Biol. 1996

    Source
    Wiki study page →
  2. PubMed

    Enhanced potency of truncated insulin-like growth factor-I (des(1-3)IGF-I) relative to IGF-I in lit/lit mice

    Gillespie C, Read LC, Bagley CJ, et al. J Endocrinol. 1990

    Source
    Wiki study page →
  3. PubMed

    In vivo actions of IGF analogues with poor affinities for IGFBPs: metabolic and growth effects in pigs of different ages and GH responsiveness

    Walton PE, Dunshea FR, Ballard FJ. Prog Growth Factor Res. 1995

    Source
    Wiki study page →
  4. PubMed

    IGF-I variants which bind poorly to IGF-binding proteins show more potent and prolonged hypoglycaemic action than native IGF-I in pigs and marmoset monkeys

    Tomas FM, Walton PE, Dunshea FR, et al. J Endocrinol. 1997

    Source
    Wiki study page →
  5. PubMed

    Insulin-like growth factor-I and its N-terminal modified analogues induce marked gut growth in dexamethasone-treated rats

    Read LC, Tomas FM, Howarth GS, et al. J Endocrinol. 1992

    Source
    Wiki study page →
  6. ClinicalTrials.gov

    des(1-3)IGF-1 / IGF-1 DES studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →
  7. FDA Drug Label

    MOUNJARO (tirzepatide) injection, for subcutaneous use - Prescribing Information

    Eli Lilly. FDA Drug Label. 2022

    Source
    Wiki study page →
  8. PubMed

    Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)

    Jastreboff AM, Aronne LJ, Ahmad NN, et al. N Engl J Med. 2022

    Source
    Wiki study page →
  9. ClinicalTrials.gov

    Tirzepatide obesity studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →
  10. PubMed

    Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.

    Frías JP, Davies MJ, Rosenstock J, et al. N Engl J Med. 2021

    Source
    Wiki study page →
  11. PubMed

    Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2).

    Frias JP, De Block C, Brown K, et al. J Clin Endocrinol Metab. 2024

    Source
    Wiki study page →
  12. FDA Drug Label

    ZEPBOUND (tirzepatide) injection, for subcutaneous use - Prescribing Information

    Eli Lilly. FDA Drug Label. 2023

    Source
    Wiki study page →
  13. PubMed

    Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

    Garvey WT, Frias JP, Jastreboff AM, et al. Lancet (London, England). 2023

    Source
    Wiki study page →
  14. PubMed

    Tirzepatide for Obesity Treatment and Diabetes Prevention

    Jastreboff AM, le Roux CW, Stefanski A, et al. The New England journal of medicine. 2025

    Source
    Wiki study page →
  15. PubMed

    GLP-1 receptor agonist discontinuation and cardiovascular events and all-cause mortality in people with type 2 diabetes: a retrospective cohort study

    Ceriello A, Prattichizzo F, Lucisano G, et al. Lancet Reg Health Eur. 2026

    Source
    Wiki study page →
  16. PubMed

    Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial

    Aronne LJ, Ahmad NN, Fletcher M, et al. JAMA. 2024

    Source
    Wiki study page →